RC
NUVB icon

Rangeley Capital’s Nuvation Bio NUVB Stock Holding History

Rangeley Capital’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,000
Closed -$25.4K – 137
2025
Q2 		$25.4K Buy
+13,000
New +$27.1K 0.03% 67

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rangeley Capital's NUVB Position: Q3 2025 in Review

Rangeley Capital sold out of Nuvation Bio (NUVB) in Q3 2025, closing a stake of 13,000 shares — an estimated $25.4K sold.

Rangeley Capital first reported a position in NUVB in Q2 2025 and held it in 1 quarter. The position peaked at $25.4K in Q2 2025. 203 funds tracked by Wall St. Rank hold NUVB as of Q3 2025.

  • Rangeley Capital reported no remaining Nuvation Bio position as of Q3 2025 after selling out during the quarter.
  • Rangeley Capital sold 13,000 Nuvation Bio shares in Q3 2025, an estimated $25.4K.
  • Rangeley Capital first reported a position in Nuvation Bio in Q2 2025 and held it in 1 quarter.
  • Rangeley Capital's Nuvation Bio position peaked at $25.4K in Q2 2025.
  • 203 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2025.

Based on Rangeley Capital's 13F filing for Q3 2025, filed 14 Nov 2025.